Discovering immune responses to tuberculosis in high disease burden populations

MYCOBACTERIUM TUBERCULOSIS PROTEOME-WIDE EPITOPE DISCOVERY AND HOST TRANSCRIPTOME-WIDE T CELL PHENOTYPING IN HIGH DISEASE BURDEN POPULATIONS

NIH-funded research Translational Genomics Research Inst · NIH-11201171

This study is looking at how our immune system responds to tuberculosis by exploring specific parts of the immune cells in people from areas where the disease is common, especially in sub-Saharan Africa, to find out what might help protect against it.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionTranslational Genomics Research Inst NIH-funded
Lab location1 site (Phoenix, United States)
Project IDNIH-11201171 on NIH RePORTER

What this research studies

This research investigates the immune responses to Mycobacterium tuberculosis by identifying thousands of CD4 T cell epitopes and their interactions with specific HLA proteins in populations heavily affected by tuberculosis, particularly in sub-Saharan Africa. Using advanced DNA-barcoded antigen assays, the study aims to uncover how these immune responses vary among individuals with different disease states. By analyzing the host's transcriptome alongside the pathogen's genome, the research seeks to pinpoint T cell characteristics that may offer protection against tuberculosis.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals from sub-Saharan African populations who are at high risk for tuberculosis or have been diagnosed with the disease.

Not a fit: Patients who do not have tuberculosis or are not from the targeted high disease burden populations may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved understanding of tuberculosis immunity and the development of more effective vaccines or therapies.

How similar studies have performed: Previous research has shown promise in identifying immune responses to tuberculosis, but this approach is novel in its comprehensive epitope discovery and focus on underrepresented populations.

Where this research is happening

Phoenix, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.